Compare Amgen, Inc. (AMGN) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs PAGSEG Inc — how do they compare? Amgen, Inc. trades at $359.29 (market cap $196.12B), while PAGSEG Inc trades at $9.33 (market cap $2.59B). The key difference: Amgen, Inc. is far larger — about 75.7× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (11.24%). Which is the better fit depends on your goals.
| AMGN | PAGS | |
|---|---|---|
Market Cap | $196.12B | $2.59B |
Sector | Health | Technology |
52-Week High | $388.16 | $12.00 |
52-Week Low | $271.18 | $7.75 |
Enterprise Value | $241.41B | $10.22B |
Dividend Yield | 2.77% | 11.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PAGS trades at $9.25, up 2.78% with neutral technical indicators showing support at $9 and resistance at $9. The stock presents strong value fundamentals with a P/E of 6.55 and P/B of 0.92, supported by solid profitability including 10.4% net margins and 14.52% ROE. Recent earnings showed mixed results with a Q1 2026 miss but Q4 2025 beat, while the company maintains robust cash flow generation of $7.56B from operations.
The investment case centers on deep valuation discounts and Brazil's rate-cutting cycle potential, though execution risks and competitive pressures remain. Analyst consensus is strongly bullish with 62.5% buy ratings, viewing current levels as attractive for long-term investors given the company's banking and credit expansion trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
